A Study of LUMIGAN® RC in the Clinical Setting

Study Identifier
CLEAR
CT.gov Identifier
NCT01833741
EudraCT Identifier
Not available
EUCTIS ID
Not available
For general inquiries, please contact

844-663-3742 or [email protected]

Study Complete

Study Details

Medical Condition
  • Glaucoma - Open Angle
  • Ocular Hypertension
    • Study Drug
  • Bimatoprost 0.01%
    • Phase
    Phase 4
    Sex
    Female & Male
    Age
    18+ years
    Inclusion and Exclusion Criteria
    Inclusion Criteria:
    * Elevated IOP due to either primary open-angle glaucoma or ocular hypertension * Determined by the treating physician to require treatment with LUMIGAN® RC
    Exclusion Criteria:
    * None

    Protocol Summary

    This study will evaluate bimatoprost 0.01% (LUMIGAN® RC) in patients with elevated intraocular pressure (IOP) due to primary open angle glaucoma (POAG) or ocular hypertension (OHT) in a clinical setting.

    Study Locations

    Location
    Status
    Location
    Barrie, Ontario, Canada
    Status
    Not applicable